Top Section/Ad
Top Section/Ad
Most recent
Offer came as markets recovered and volatility fell
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
Eight banks provided loan facility to company
More articles/Ad
More articles/Ad
More articles
-
Existing shareholders took a large chunk of the deal, 30% of bidders left empty-handed -
Calmer book builds than earlier trades hint at less guesswork over pricing
-
An end-of-year surge in deal-making has sparked predictions of a boom in leveraged buy-outs
-
Italian pharmacy group to refinance €460m of debt and pursue acquisitions
-
Bumpy ride ahead but investors see emerging markets as big beneficiaries
-
Top tier name profits from its track record to pay lower upfront costs
